Novo Awaits EMA’s Verdict On Oral Form Of Antidiabetic Blockbuster Semaglutide
Alnylam’s Givlaari for acute hepatic porphyria is also among the 14 new products that could get an EU approval recommendation this week.
You may also be interested in...
Ozempic's continued good growth and the ongoing roll out of oral Rybelsus should revitalize growth and expand Novo's reach in the diabetes market this year.
A plethora of new drugs moved closer to the EU market this week after the European Medicines Agency recommended that they should be approved.
Products from Novartis, Celgene and Merck could get an EU approval recommendation at this week's CHMP meeting.